pfizer_logo

Pfizer India names S Sridhar MD

March 21, 2016
Business Services, Sales and Marketing Executive appointment, Pfizer Inc, Pfizer India

Pfizer India (BOM: 500680) has named S Sridhar the company’s managing director for a five-year term, effective March 18. Sridhar …

tablet_production_2

Further positive trial results boost Amgen and UCB’s romosozumab

March 21, 2016
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval

Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …

celgene

Celgene’s ozanimod meets endpoints in Phase II ulcerative colitis trials

March 21, 2016
Research and Development, Sales and Marketing Celgene

Celgene International Sàrl, a Celgene subsidiary, has announced additional data of exploratory endpoints from a Phase II trial of ozanimod …

US FDA rejects application for Eagle Pharma’s blood thinner; shares plunge

March 21, 2016
Research and Development, Sales and Marketing Eagle Pharmaceuticals, Kangio, US FDA, blood thinner

Shares in Eagle Pharmaceuticals (Nasdaq: EGRX) closed down almost 19% Friday after the US Food and Drug Administration rejected the …

pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016
Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …

janssen_stairs_1

J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease

March 18, 2016
Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease

Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …

abraxane0058

Wales approve pancreatic cancer drug for use despite NICE rejection in England

March 18, 2016
Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval

Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …

Study data supports switch to Celltrion’s Remicade biosimilar

March 18, 2016
Research and Development

Celltrion and distribution partner Mundipharma have presented study data supporting switching irritable bowel disease (IBD) patients from Remicade to biosimilar …

shutterstock_92671375

Indian govt set to ban 1,200 fixed-dose combination drugs, reports

March 18, 2016
Business Services, Medical Communications, Sales and Marketing Abbott Laboratories, Pfizer, cough drug, pharma

Indian regulators are set to ban an additional 1,200 fixed-dose combinations, sent for probe by Drug Controller General of India …

clinical_trial-web

OncoMed initiates Phase Ib immuno-oncology combination clinical trial

March 18, 2016
Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib

OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …

allergan

Allergan files ANDA for generic version of Celgene’s breast cancer treatment

March 18, 2016
Business Services, Medical Communications, Sales and Marketing Abraxane, Allergan, Celgene, breast cancer, generic

Allergan (NYSE: AGN) said it is seeking regulatory approval for a generic version of biotech firm Celgene’s (Nasdaq: CELG) breast …

zydelig_gilead

Gilead cancer boss departs after safety concerns halt Zydelig trials

March 18, 2016
Medical Communications, Research and Development Gilead Sciences, zydelig

In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …

Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma

March 18, 2016
Medical Communications, Research and Development Gentech, Roche, kite pharma, non-Hodgkin lymphoma

Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy …

breckenridge_pharma

FDA approves Breckenridge’s generic of Pfizer’s anti-epilepsy drug

March 18, 2016
Research and Development, Sales and Marketing FDA, Neurontin, Pfizer, anti-epilepsy, approval, breckenridge, gabapentin, tris pharma

Breckenridge Pharmaceutical Inc. has announced that their generic of Pfizer’s anti-epilepsy drug Neurontin (gabapentin) has been approved by the US …

msd

Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi

March 17, 2016
Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis

US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …

shutterstock_95714119

Vitae Pharma soars on positive mid-stage trial results for psoriasis drug

March 17, 2016
Business Services, Research and Development, Sales and Marketing Vitae Pharmaceuticals, drug trial, psoriasis, research

Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis …

alm_v2

Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million

March 17, 2016
Business Services, Sales and Marketing Almirall, Grünenthal Group, merger and acquisition

Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about â‚¬50 million ,to …

bayercross3

FDA approves Bayer haemophilia A drug Kovaltry

March 17, 2016
Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound

Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …

amgen_sign_on_wall

Amgen wins high-profile cholesterol drug patent case v Sanofi

March 17, 2016
Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent

A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …

The Gateway to Local Adoption Series

Latest content